New vax “could prevent 90% of cervical cancer cases”

With strong new evidence published this week, the PBAC has recommended the 9-valent HPV vaccine replace the current quadrivalent one In response to a request from manufacturer Seqirus, the Pharmaceutical Benefits Advisory Committee (PBAC) has recommended that Gardasil 9 be listed on the National Immunisation Program as a two-dose schedule for females and males, aged 12-13